Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00291057 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice
A Phase 2 study, sponsored by Sun Pharmaceutical Industries.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00291057: Clinical Trial Phase 2 study, sponsored by Sun Pharmaceutical Industries.
NCT00291057 is a Phase 2 study that was terminated before completion, run by Sun Pharmaceutical Industries. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00291057, a Phase 2 study, was terminated before completion, sponsored by Sun Pharmaceutical Industries.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.
Interventions
- DRUG MALG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Why NCT00291057 stopped before completion
NCT00291057 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which MALG is the first listed.
NCT00291057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00291057 about?
NCT00291057 is a clinical study titled "Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice". In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and...
What is the current status of trial NCT00291057?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2006-02. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00291057?
The interventions under investigation include: MALG (DRUG).
Who is sponsoring clinical trial NCT00291057?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00291057's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia